Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468728 | 1.00 | FKBP1A (0.50) | FKBP1AL3MBTL1 | |
| SCHEMBL468768 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL31632739 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL468913 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL31632697 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL468767 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL468915 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL31632734 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL27173066 | 0.99 | FKBP1A (0.49) | FKBP1AL3MBTL1 | |
| SCHEMBL468710 | 0.95 | FKBP1A (0.51) | FKBP1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357792-B2 | Method of administration and treatment | Dyvve Biosciences, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| CN-114404424-A | A pharmaceutical composition for treating alopecia, and its preparation method | 硬核医药科技(上海)有限公司 | 2022-04-29 | — | — | CN | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| EP-4349414-B1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION | DYVE BIOSCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250262239-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250195664-A1 | TRANSDERMAL CARRIER | DYVE BIOSCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12310983-B2 | Method of administration and treatment | DYVE BIOSCIENCES, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240424016-A1 | BUFFERING FOR NON-ALCOHOLIC STEATOHEPATITIS AND LIVER DISEASES | DYVE BIOSCIENCES, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| US-20070183936-A1 | Apparatus and methods for evaluating the barrier properties of a membrane | NUVO RESEARCH US, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2006091297-A2 | MOLECULES TO ENHANCE PERCUTANEOUS DELIVERY AND METHODS FOR DISCOVERY THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1680223-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | Fqubed, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005012549-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | FQUBED, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195664-A1 | TRANSDERMAL CARRIER | NACA, ETF1, SUCLG1 | FKBP1A 441/4885L3MBTL1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.